Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1831-1838

  Stellas, Dimitris ^a,b   Karameris, Andreas ^c   Patsavoudi, Evangelia ^a,b  

^a UNIVERSITY OF WEST ATTICA   (Greece)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c Veterans Administration Hospital (NIMTS)   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; HEAT SHOCK PROTEIN 90; MATRIGEL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4C5; PARAFFIN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTIGEN; ANTIGEN 4C5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CANCER INVASION; CELL SURFACE; CONTROLLED STUDY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INOCULATION; MELANOMA; MELANOMA B16; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TISSUE MICROARRAY; WOUND HEALING; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; EVALUATION; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; MORTALITY; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION;

EID: 34250172746     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1585     Document Type: Article

References (28)

1. Hartson SD, Matts RL. Association of Hsp90 with cellular Src-family kinases in a cell-free system correlates with altered kinase structure and function. Biochemistry 1994;33:8912-20.
2. Hartson SD, Barrett DJ, Burn P, Matts RL. Hsp90-mediated folding of the lymphoid cell kinase p56lck. Biochemistry 1996;35:13451-9.
3. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995;270:24585-8.
4. Helmbrecht K, Zeise E, Rensing L. Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 2000;33:341-65.
5. Dittmar KD, Pratt WB. Folding of the glucocorticoid receptor by the reconstituted Hsp90-based chaperone machinery. The initial hsp90.p60.hsp70- dependent step is sufficient for creating the steroid binding conformation. J Biol Chem 1997;272:13047-54.
6. r approximately 90,000 heat shock protein: an important modulator of ligand and DNA-binding properties of the glucocorticoid receptor. Cancer Res 1989;49:2275-81s.
7. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23:1078-87.
8. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
9. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73.
10. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24.
11. Workman P. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. Cancer Detect Prev 2002;26:405-10.
12. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
13. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
14. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
15. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14:1169-76.
16. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 2005;11:3385-91.
17. Thomaidou D, Patsavoudi E. Identification of a novel neuron-specific surface antigen in the developing nervous system, by monoclonal antibody 4C5. Neuroscience 1993;53:813-27.
18. Sidera K, Samiotaki M, Yfanti E, Panayotou G, Patsavoudi E. Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system. J Biol Chem 2004;279:45379-88.
19. Yfanti E, Nagata I, Patsavoudi E. Migration behavior of rodent granule neurons in the presence of antibody to the 4C5 antigen. J Neurochem 1998;71:1381-9.
20. Yfanti E, Sidera K, Margaritis LH, Patsavoudi E. The 4C5 antigen is associated with Schwann cell migration during development and regeneration of the rat peripheral nervous system. Glia 2004;45:39-53.
21. Thomaidou D, Dori I, Patsavoudi E. Developmental expression and functional characterization of the 4C5 antigen in the postnatal cerebellar cortex. J Neurochem 1995;64:1937-44.
22. Becker B, Multhoff G, Farkas B, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 2004;13:27-32.
23. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
24. Tzinia A, Soteriadou KP. Substrate dependent pH optima of gp63 purified from seven strains of Leishmania. Mol Biochem Parasitol 1991;47:83-9.
25. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness. Nat Cell Biol 2004;6:507-14.
26. Price JT, Quinn JMW, Sims NA, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res 2005;65:4929-38.
27. Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2005;11:3889-96.
28. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006;5:522-32.